Clinical Report: Combining Multi-Omics Approaches and Machine Learning to Investigate Amino Acid Metabolism's Impact on Intervertebral Disk Degeneration
Overview
Expand on the implications of the five-gene core signature for clinical practice.
Background
Intervertebral disc degeneration (IDD) is a leading cause of chronic low back pain and poses significant public health challenges, particularly in aging populations. Understanding the molecular underpinnings of IDD, particularly the role of amino acid metabolism, is crucial for developing effective diagnostic and therapeutic strategies. Current treatments primarily focus on symptom management, highlighting the need for novel biomarkers and targeted interventions.
Data Highlights
Gene
Expression Change
CETP
Up-regulated
AIFM1
Up-regulated
GM2A
Up-regulated
PNPLA2
Down-regulated
AGK
Down-regulated
Key Findings
Identified 43 genes associated with altered amino acid metabolism in IDD.
Five pivotal genes (CETP, AIFM1, GM2A, PNPLA2, AGK) were selected based on differential expression.
The nomogram prediction model achieved an AUC of 0.812, indicating strong predictive capability.
Molecular docking analyses revealed potential interactions between AIFM1 and compounds NVP-AEW541 and EGCG.
Clinical Implications
The identification of specific biomarkers related to amino acid metabolism may facilitate early diagnosis and targeted therapies for IDD. Clinicians should consider these biomarkers in the context of patient management and treatment planning for chronic low back pain.
Conclusion
The study underscores the importance of amino acid metabolism in IDD and presents a promising framework for future research and clinical applications. Further validation of the identified biomarkers is essential for their integration into routine clinical practice.
